Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 979.13 Million SEK | 34.34% |
| 2022 | 728.82 Million SEK | 241.82% |
| 2021 | 213.21 Million SEK | 4354.99% |
| 2020 | 4.78 Million SEK | -21.15% |
| 2019 | 6.07 Million SEK | 0.0% |
| 2018 | - SEK | -100.0% |
| 2017 | 470 Thousand SEK | -98.43% |
| 2016 | 30 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion SEK | 3.83% |
| 2024 Q2 | 1 Billion SEK | -0.82% |
| 2023 FY | 979.13 Million SEK | 34.34% |
| 2023 Q3 | 770.16 Million SEK | -1.21% |
| 2023 Q2 | 779.56 Million SEK | 4.37% |
| 2023 Q1 | 746.89 Million SEK | 2.48% |
| 2023 Q4 | 979.13 Million SEK | 27.13% |
| 2022 Q2 | 458.02 Million SEK | 113.54% |
| 2022 FY | 728.82 Million SEK | 241.82% |
| 2022 Q1 | 214.49 Million SEK | 0.6% |
| 2022 Q3 | 467.31 Million SEK | 2.03% |
| 2022 Q4 | 728.82 Million SEK | 55.96% |
| 2021 Q1 | 1.31 Million SEK | 50.23% |
| 2021 FY | 213.21 Million SEK | 4354.99% |
| 2021 Q4 | 213.21 Million SEK | 13.76% |
| 2021 Q3 | 187.42 Million SEK | 5288.93% |
| 2021 Q2 | 3.47 Million SEK | 163.68% |
| 2020 Q1 | 2.33 Million SEK | -61.48% |
| 2020 Q2 | 1.67 Million SEK | -28.53% |
| 2020 FY | 4.78 Million SEK | -21.15% |
| 2020 Q4 | 878 Thousand SEK | -15.09% |
| 2020 Q3 | 1.03 Million SEK | -38.12% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q4 | 6.07 Million SEK | 44.18% |
| 2019 Q3 | 4.21 Million SEK | -13.46% |
| 2019 Q2 | 4.86 Million SEK | 0.0% |
| 2019 FY | 6.07 Million SEK | 0.0% |
| 2018 FY | - SEK | -100.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 470 Thousand SEK | 0.0% |
| 2017 FY | 470 Thousand SEK | -98.43% |
| 2016 FY | 30 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -5982.705% |
| Ziccum AB (publ) | 857 Thousand SEK | -114151.225% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -19565.254% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -3898.42% |
| Genovis AB (publ.) | 79.32 Million SEK | -1134.409% |
| Intervacc AB (publ) | 181 Thousand SEK | -540857.459% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -4650.536% |
| Active Biotech AB (publ) | 3 Million SEK | -32537.767% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -1523.716% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -19482.66% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -1271.162% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -12408.086% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -230827.594% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | -801.596% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -31793.583% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -37850.891% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -97813.3% |
| Camurus AB (publ) | 24.5 Million SEK | -3895.32% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -3451.959% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | -12.964% |
| Cyxone AB (publ) | 858 Thousand SEK | -114018.065% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -57125.774% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -2560.109% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -146916.967% |
| SynAct Pharma AB | 637 Thousand SEK | -153610.047% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -115092.118% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -55500.965% |
| BioInvent International AB (publ) | 23.24 Million SEK | -4112.412% |
| Alzinova AB (publ) | 800 Thousand SEK | -122291.625% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -819.486% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -126553.516% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -979.053% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -3092.27% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | -322.99% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -92183.977% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |